MarketInOut Stock Screener Log In | Sign Up

Lakefront Biotherapeutics ADR

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Lakefront Biotherapeutics ADR stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,127.16 mln
Float49.01 mln
Earnings Date11/12/2026

EPS

10.52
Robust

P / E

3.07
Deeply undervalued

Piotroski F-Score

6 / 9
Solid

Beneish M-Score

1.04
Highly suspicious

1-Year Forecast

30.33
Limited downside

Relative Strength

89 / 100
Strongly outperforming

Business Description

Lakefront Biotherapeutics NV is a Belgian biotechnology company, founded in 1999 and headquartered in Mechelen, that develops treatments for cancer and immune system diseases across the United States and Europe. The company has several drugs in clinical testing, including therapies for conditions such as lupus, lymphoma, and multiple myeloma, with some of its most advanced treatments produced directly at the point of patient care. It works in partnership with Gilead Sciences and was previously known as Galapagos NV before changing its name in May 2026.

Key Fundamentals

EPS10.52
P/E3.07
ROE20.10
RPS17.72
ROIC92.58
ROA17.09
Interest Cover309
EBITDA, mln674
EV / EBITDA-0.45
EV / EBIT-0.45
Revenue, mln1,153

Quote Details

Last 32.28
Change -0.05 (-0.15%)
Open 32.42
Volume 164,054
Turnover 5,295,663
Average Volume 264,410

Financial Ratios

Pre-Tax Profit Margin58
Leverage Ratio1.04
Current Ratio32.83
Price / Book0.57
Price / Tangible Book0.74
Debt / Equity0.00
Price / Sales1.88

Financial Strength

Altman Z-Score14.46
Piotroski F-Score 6 / 9
Beneish M-Score1.04
Price to Graham Number0.28
1-Year Target Price30.33
Short Ratio3.95
Short % of Float3.50

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 1.99% 80 / 100   
1 Month 11.85% 93 / 100   
2 Months 14.75% 90 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog